BDNF and pancreatic adenocarcinoma: To verify the value of BDNF in clinical treatment for PAAD, we explored the associations between BDNF expression and the efficacy of common administrating chemotherapeutic drugs, and the results revealed that higher BDNF mRNA levels were remarkably correlated with IC50 of chemotherapeutics, such as gemcitabine (p = 0.037), rapamycin (p = 0.027), obatoclax mesylate (p < 0.001), AKT inhibitor VIII (p = 0.046), and JNK inhibitor VIII (p = 0.021).